Tools and Methods to Enhance Tumor Cell Killing by CAR-T cells
Scale or prepare manufacturing, process control, GMP readiness and quality workflows.
Offer overview
What this offer helps you achieve
Scale or prepare manufacturing, process control, GMP readiness and quality workflows.
Scientific and technical scope
Our technology enhances CAR-T efficacy by boosting their production of type I interferon (IFN-I). Institut Curie researchers discovered that NF-kB, controlled by the RELA protein, regulates IFN-I expression in T-cells. By introducing the RELA K5R mutant into CAR-T cells, we significantly increase IFN-I levels, improving CAR-T cell effectiveness for all patients. This breakthrough offers a powerful and reliable solution for more effective CAR-T therapies.
Capabilities mobilised
Therapeutic areasFormulation and synthesisValidation using preclinical modelsBioproduction
Application fields
Oncology
Discuss this offer
Could this capability strengthen your R&D programme?
Present your scientific, technical or clinical need and identify the most relevant route to collaboration.
Continue exploring
Related expertise for your programme
Offers selected through shared capabilities, application fields or institute expertise.
